Octylphenol polyoxyethylene ethers started making waves in chemical industries during the push for more effective surfactants in the early twentieth century. Back then, the growing industrial sector wanted better control over solubility and emulsification, especially as pharmaceutical and personal care sectors expanded. Companies shifted from simple alcohol-based surfactants toward ethoxylated variants, attracted by their improved performance. OP-40’s journey into the pharma grade market can be traced to an industry-wide demand for higher-purity, more consistent products. As regulations tightened across the globe, research labs and chemical producers began focusing on reducing impurities, managing batch consistency, and guaranteeing safety profiles detailed enough to meet British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) standards.
Octylphenol Polyoxyethylene Ether 40, often shortened to Op-40, stands as a non-ionic surfactant based on the attachment of about 40 ethylene oxide units to an octylphenol core. This choice—forty units—relies on a need for higher hydrophilicity, which directly reflects on its performance in pharmaceutical formulations. In practice, Op-40 finds its main use as a solubilizer for poorly water-soluble drugs and helps maintain the physical stability of emulsions and creams used in therapy or delivery systems. From tablet coatings to topical gels, Op-40 helps active pharmaceutical ingredients (APIs) do their job, which directly impacts patient outcomes. For those in labs and production floors, it’s less about formulating with just any surfactant and more about getting reliable results lot after lot.
Op-40 usually appears as a clear to slightly hazy liquid. Its color spectrum sticks close to colorless or pale yellow, and it brings a mild, non-offensive scent—nothing that would mask or interact badly with drug aromas. Viscosity rides higher as compared to compounds with fewer ethylene oxide chains. Water solubility towers above shorter-chain analogs, and its performance scales up with increased EO content. Its average molecular weight lands around 1800–2200 g/mol because each ethoxylation pushes up the number. Surface tension reduction runs effective in both cold and warm water, and I’ve found that it doesn’t let up even in higher salt or ionic stress, making it reliable for a range of drug formulations. The cloud point usually sits above 80°C, which helps during manufacturing steps involving heat.
Pharma grade Op-40 demands rigorous quality checks. Manufacturers must provide data sheets marking exact EO content, specification on free phenol, pH of 1% aqueous solution (typically 6-8), and absence of impurities like dioxane or heavy metals. Labels must clearly note batch numbers, shelf life, storage limits, and allergen-free status, because supply chain transparency helps cut down on recalls or production errors. Since I’ve overseen audits of excipient suppliers, I know regulators always check for compliance with BP, EP, and USP monographs—testing for peroxide content, residual solvents, and microbial limits. This part of the process makes life easier downstream by lowering the odds of product rejection during validation.
The bulk of Op-40 floods out of industrial reactors set up for controlled ethoxylation. Octylphenol acts as the base, and ethylene oxide gas gets added stepwise, usually under pressure and in the presence of a catalyst like potassium hydroxide. Temperature management matters—a runaway ethoxylation can spike temperatures, so jacketed vessels and cooling loops keep things reined in. Ethoxylation pushes the degree of polymerization but must be stopped at the sweet spot to avoid distributing too many short or long EO chain products. Once the reaction finishes, stripping steps remove leftover ethylene oxide and volatile alcohols. Purification includes vacuum distillation and sometimes liquid-liquid extraction if high grades are needed. These steps don’t just boost purity; they also make sure the end product behaves predictably in pharma uses.
Op-40's reactive core, octylphenol, lets manufacturers tweak characteristics. Further ethoxylation or partial sulfation generates surfactants with altered foaming or emulsifying power. Cross-linking agents can attach to the polyether chains to form specialized conjugates useful in slow-release drug platforms. Pharmaceutical scientists may also introduce terminal functional groups to attach ligands or targeting moieties for drug delivery vehicles. Analytical chemists employ NMR, IR, and SEC/GPC to track the degree of modification, since changes right down to individual EO units affect viscosity and solubilization power. These chemical modifications connect Op-40’s legacy as a multitasker in both conventional and advanced pharmaceutical research.
Trade and lab names for Op-40 vary widely. You’ll spot labels such as Polyoxyethylene (40) Octylphenyl Ether, Octoxynol-40, or by brand-names like Triton X-405 or Renex 40. Synonym confusion can lead to error, especially if purchasing for GMP sites, so cross-checking Chemical Abstracts Service (CAS) numbers and compliance certificates is routine. Accurate records and supplier questionnaires work better than any shortcut in locating the true product.
Manufacturers expect robust safety protocols due to persistent concerns about phenolic raw materials. Skin and eye contact may cause irritation, so gloves, splash goggles, and lab coats are standard. Dust is not an issue for liquid grades, but aerosol generation during pumping or mixing demands local exhaust ventilation. Overexposure to vapors or accidental combustion products—such as carbon monoxide and phenols—requires emergency plans. Pharma operations need SOPs verifying response plans for leaks or spills, plus waste streams disposal that complies with environmental rules. Toxicology data and workplace air monitoring further reduce exposure incidents. Every handler must understand MSDS warnings and report mishaps for root-cause analysis.
Op-40 plays a vital role in pharma formulations. It solubilizes active ingredients in oral liquids and suspensions, contributing to consistent dosing and patient safety. In creams and gels, it stabilizes emulsions and ensures that APIs remain evenly distributed. Vaccine development benefits from Op-40 in adjuvant mixes, enhancing immune response without compromising antigen structure. Sterile production lines count on it to disperse hydrophobic agents in injectable solutions. The reliability earned Op-40 spots outside pharmaceuticals, including in diagnostic reagents and laboratory research.
Lab teams everywhere keep pushing Op-40 into novel roles. Recent research focuses on using ethoxylate surfactants as drug delivery enhancers—improving oral bioavailability or promoting tissue penetration. Researchers explore PEGylation using Op-40 chains as linkers for biologic drugs, hoping to cut immune reactivity and improve drug tolerance. With rising antibiotic resistance, scientists are investigating whether tailored surfactant derivatives can trigger membrane disruption in pathogens. Analytical labs keep refining HPLC, GC, and mass spectrometry methods for impurity profiling. For research teams, Op-40 adapts well to both traditional wet chemistry and new drug delivery systems.
Concerns about nonylphenol and octylphenol derivatives reflect in ongoing studies on Op-40. Some regulatory groups keep an eye on endocrine-disrupting potential, owing to the phenol backbone seen in environmental toxicity research. Results show Op-40's biocompatibility greatly improves in pharma grades, thanks to purification, but its breakdown products in aquatic environments encourage stricter disposal controls and closed-loop processes. In human safety studies, local irritation remains the standout risk, and recent review articles report very low systemic toxicity at doses used in excipients. Still, environmental watchdogs push industry toward greener alternatives, citing solid evidence of persistent phenolic residues in run-off water and soil.
The outlook for Op-40 grows complex as pharma chases safer, more sustainable excipients. Companies already invest in greener ethoxylation processes, swapping out hazardous catalysts in favor of recyclable ones and improving production yields to minimize waste. Researchers scan for plant-based non-phenolic alternatives but acknowledge it’s tough to match Op-40’s stability and performance. Drug companies exploring biologics and nanoparticle-based medicines look to Op-40 for compatibility studies, while regulatory agencies update risk assessments based on fresh ecotoxicology data. My experience tells me that Op-40 will hold its ground in legacy applications as compliance gets tighter, but new blends and analogs inspired by Op-40 chemistry will likely define the next decade in excipient innovation.
Spend time around any pharmaceutical lab, and you start noticing certain names pop up more than others. Octylphenol Polyoxyethylene Ether 40, known in the business as OP-40, is one of those unsung workhorses you’ll spot on ingredient lists for everything from creams to oral suspensions. Most people outside the field wouldn’t give OP-40 a second glance, but ask a formulation chemist, and a whole story unravels.
Stirring oil into water brings you back to science class. They separate, no matter how hard you whisk. OP-40 solves this riddle. Its chemistry works much like a matchmaker at an awkward party, getting the oil and water to mix and stick together. Pharmaceutical creams and lotions depend on stable mixtures to spread soothing and active molecules evenly across the skin. OP-40 makes that possible, bottle after bottle.
Take oral suspensions, where active ingredients must float in liquid long enough for a full dose. Without the right surfactant, those tiny particles would clump or sink, throwing off the safe dose. OP-40 keeps these particles where they should be, dose after dose.
Drug companies don’t gamble with additives. They run through long checklists before anything lands in a medicine, and that includes OP-40. It has to meet tough standards set by respected bodies like the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP). These standards write the rulebook for how pure, consistent, and safe a substance must be before it goes anywhere near a pill, syrup, or ointment.
Working with these standards turns an everyday chemical into a pharmaceutical-grade ingredient. In my own work, picking a certified grade cut down on headaches from batch failures or red tape, helping projects move smoothly from the benchtop to the clinic.
Every ingredient in a pharmacy product brings up the question: Will it cause a reaction? OP-40 keeps showing a strong safety record over decades of use, but success stories came from strict testing, vigilant regulation, and controlled sourcing. Families and patients trust that what’s in their medicine works and won’t cause harm. That trust grows out of strong science, tested suppliers, and manufacturers who never cut corners.
Despite OP-40’s benefits, the industry faces questions over its environmental impact and potential for residue in finished products. Governments and scientists keep studying both the direct and side effects of all surfactants in pharmaceuticals. This constant scrutiny feels reassuring. If an ingredient needs to be swapped out, I’ve seen dedicated teams roll up sleeves and hunt down safer, greener alternatives with similar benefits. Circular economies and green chemistry teams are already mapping out better surfactants for the next generation of medicines.
OP-40 earned a reputation through decades of safe, effective service in the industry. Its ability to pull together water and oil in drug delivery remains essential. As the pharma world responds to rising expectations for safety, greener practices, and transparency, the story of OP-40 reminds us that every piece of a formula deserves respect. Behind every name on an ingredient list, there’s usually a reason built on hard lessons, shared expertise, and full transparency.
OP-40 has made a name for itself in the pharmaceutical industry as an excipient for both solid dose and powder blends. Behind the scenes, this ingredient shapes how pills break down and absorb in the body. In manufacturing, reliability comes from getting the right flow, compression, and stability – all boxes OP-40 manages to tick, thanks to its unique blend of physical properties and chemical reliability.
Every batch of OP-40 shares telling characteristics. The substance typically forms a white to off-white powder. Its compressibility and density mean that tablet makers rarely struggle to press a consistent pill every cycle. Most suppliers specify a bulk density between 0.55-0.75 g/mL, which translates to predictability when loading machinery or metering out blends.
Moisture matters. OP-40 usually offers a loss on drying around 3% or less, protecting sensitive actives from early degradation and helping tablets keep shape in humid climates. Tapping a handful of OP-40 reveals its granular, free-flowing nature, which cuts down on sticking and clumping during both storage and mixing. This saves companies from constant machine clean-ups and keeps costs in check.
Diving into OP-40's chemical background, it draws power from partially pregelatinized starch. This means the granules have been heat-treated just enough to swell but not dissolve. The result? It forms a mild binder during processing. No need for added chemicals or extra binders — pure formulation simplicity.
Quality assurance teams often demand a pH in the range of 4.5 to 7.0 for inactive agents like this. OP-40 consistently lands in that window, which suits most active pharmaceutical ingredients and minimizes risk of unwanted reactions.
The biggest issue in tablet production? Consistency. OP-40's granular structure lets it slip through hoppers smoothly, saving on both time and waste. Its particle size distribution, often averaging 40-100 microns, aligns perfectly with fast-dissolving needs and uniform mixing. The particles don’t cake together in storage, either—a headache with many other starches.
Thanks to its partial gelatinization, OP-40 does more than play filler. It binds powder, keeps active ingredients evenly distributed, and boosts disintegration once swallowed, so patients benefit from rapid release and reliable dosing. Quality data show this ingredient resists breakage and chipping, delivering tablets that won’t crumble under shipping stress.
Modern production standards call for low microbiological content and absence of common allergens like gluten. Trusted OP-40 sources meet strict QC for bacterial, yeast, and mold levels, making the ingredient a confident choice for manufacturers worried about recalls or regulatory hurdles. In finished products, OP-40 doesn’t add calories or cause digestion issues, given its inert status.
Today’s pharmaceutical world doesn’t accept downtime or dosing errors. The details behind OP-40—steady compressibility, reliable moisture control, clean chemical profile—show why it remains a go-to excipient. For manufacturers, the right starter ingredient makes all the difference in total cost, regulatory compliance, and patient safety. OP-40 sticks around because it quietly checks all the essential boxes where others often slip up.
People don’t lift a bottle of medicine and wonder about the stories behind its ingredients, but they should. OP-40, a widely used excipient in drug formulations, turns up in countless tablets and capsules. Its safety and compliance with major pharmacopeia standards—BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia)—matter far more than most notice. I’ve come to realize that, behind every effective pill, there are layers of checks protecting patient health, all rooted in these standards.
OP-40 doesn’t show up randomly in medicines; it’s chosen for specific properties, but none of those matter if it misses the critical tests laid out by the pharmacopeias. BP, EP, and USP set the tone for acceptable purity, strength, and safety. These aren’t just lines on paper—they come from years of scientific scrutiny and regulatory lessons learned the hard way. If OP-40 fails these tests, all trust in the final medicine crumbles. I’ve seen companies stumble here, discovering contaminants in lots that otherwise looked perfectly fine.
The pharmacopeias do more than lay out a list of chemical tests. They spell out tests for impurity levels, bacterial contamination, heavy metals, and physical characteristics such as moisture. Passing means samples of OP-40 consistently meet—or beat—these expectations. One batch might look on point, but it doesn’t count unless every shipment stays steady. Skipping routine checks can land patients, companies, and health authorities in crisis mode. Contaminated excipients have led to large-scale recalls before, so the bar sits high for a reason.
Regulatory agencies look to the pharmacopeias as their backbone. If OP-40 claims compliance with BP, EP, and USP, it means regulators will cross-check the supporting data. This includes certificates of analysis, detailed batch records, and sometimes independent lab verification. Having walked through an audit before, I can say that the inspectors don’t stop at paperwork—they ask about everything from supplier quality to transport chain. Shortcuts invite trouble.
When auditors catch gaps—maybe microbial counts that show up too frequently, or assay values floating outside allowed limits—they want answers. Weak processes and poor documentation can halt production or cause costly recalls. Lax standards have endangered lives in the past. Pharmaceutical history carries grim examples of diethylene glycol contamination and nitrosamine scares. The lesson always lands the same way: only trusted, compliant excipients like OP-40 belong in the process.
A clear path to trust in OP-40 begins with transparent reporting and regular independent verification. Third-party labs play a big role, offering unbiased results that can back up internal quality control. Companies should publish summaries of their compliance data—not only to reassure regulators but also because educated patients deserve to know what sits inside their medicine cabinets. Batch traceability, which tracks every shipment from source to shelf, ensures that if a problem pops up, companies can act quickly and protect the people who rely on their products.
Continuous improvement beats a “one-and-done” outlook. Advancements in analytical methods can sharpen the screening for impurities and promote safer drug supplies. Investment in better facilities and staff training helps companies stay ahead of new regulatory changes. With so much riding on compliance, the stakes around OP-40 never drop. Every safe dose taken today comes from the hard lessons and diligent checks that shape this industry.
Most folks don’t stop to think about the nitty-gritty of storing chemicals, but mistakes in this department hit safety, product quality, and the bottom line. OP-40 is no exception. I’ve seen companies lose entire batches and face worker safety scares from simple storage slip-ups. The rules exist for a reason, usually written in pain or panic somewhere else. Getting these steps right becomes a real act of respect for everyone's time and health.
OP-40 tends to show up in labs and plants where there’s a need for reliable raw materials. It doesn’t take much—heat, water, or sloppy storage practice—before it breaks down or reacts with things it shouldn’t. There’s a financial impact if it spoils, but a much bigger headache comes from chemical burns or vapor releases in the workplace. So, good stewardship makes sense for anyone in this business.
First thing—always keep OP-40 in a tightly sealed original drum or container. Once that seal breaks, air and moisture start working against you. Pick a storage spot where the temperature stays steady, out of direct sunlight. Most manufacturers say somewhere below 25°C, away from steam lines and heat sources. From my experience, even a short stint above those temps can leave you with a sludge nobody trusts.
Choosing a dry location keeps caking and clumping at bay. OP-40 can turn lumpy just from a humidity spike in the warehouse. Stack containers on pallets off the ground; avoid concrete and cold floors where condensation builds up and creeps under lids. If the drum or bag picks up moisture, not only does the material degrade, but cleaning it out gets expensive fast—plus it slows down production lines.
Don’t park OP-40 near food processing or drinking water supplies. The right chemical label and secondary containment mean that if a leak hits, it won’t make its way where it shouldn’t. Using color-coded bins or locked cages helps crew members keep different chemicals straight—label blindness causes more close calls than folks like to admit.
People who move or measure out OP-40 in a plant deal with the risk firsthand. Workers should wear gloves and splash protection. Even tiny amounts can irritate the skin or eyes. For bulk operations, line up a fume hood or strong extraction fan. Tiny particles hang in the air and drift a lot farther than people expect. From what I’ve seen, spending a little extra on proper PPE and local exhaust pays off in fewer sick days and less staff turnover down the line.
Teams need a cleanup kit handy—a neutralizing agent if needed, plus absorbent pads and airtight waste bins. I’ve seen shifts grind to a halt when a minor spill turns into a frantic search for supplies. Good prep prevents chaos. Teach everyone where the safety shower and eyewash stations sit. Emergency plans should get a dry run every few months; panic is no friend in a crisis.
OP-40 isn’t a compound to take lightly. Every accident I’ve heard about traced back to rushing or ignoring the basics. Reliable suppliers usually pass along their recommended shelf life and handling rules—using that info and keeping storage areas tidy prevents a long list of headaches.
Medicine depends on active ingredients arriving in pristine shape from factory to pharmacy. OP-40, a popular excipient for modified-release tablets, comes packed with serious care. No one wants contaminants, moisture, or rough handling messing up batch quality. The way manufacturers ship OP-40 says a lot about how seriously the world takes drug safety and reliability. Without solid packaging, simple humidity or an accidental tear could spell disaster on the production line.
Based on years watching pharmaceutical supply chains, bulk excipients like OP-40 rarely arrive in glass jars or small bottles. Instead, the industry counts on heavy-duty, food-safe sacks—usually lined polyethylene or laminated bags inside stiff drums. The primary bag keeps out air and moisture, locking in a tight, dry environment that knots up mold or bacterial threats before they start. Most shipments tip the scales at 20 to 25 kilograms per drum or sack, so workers can handle them without special machinery, but the load still fits industrial batch needs in modern plants.
Every unopened container gets a label printed with lot number, manufacturing date, expiration, and source. People sometimes overlook these tags as boring paperwork, but this information saves lives if something ever goes wrong on the market. If one batch faces a recall, supply chain teams trace every shipment right to the end. Good labeling practices guard against mix-ups between chemically similar-looking powders—a real problem in busy warehouses. Proper record-keeping also keeps companies in line with regulators who audit every detail, from shipping documents to finished tableting processes.
Big containers create storage headaches. If a bag rips, the powder can clump or draw in contaminants almost instantly. Temperature swings in non-climate-controlled storage rooms coax moisture through even the best seals, slowly changing the flow and compressibility that tablet makers depend on. In some regions, pests and insects break through weak packaging and introduce physical impurities. Risk like this forces drug makers to always double-check seals and avoid excessive stacking, as heavy loads squeeze lower bags and risk splits at the seams.
OP-40 packaging practices prove that pharmaceutical safety starts at the warehouse. Tamper-evident tape, thick liners, and tough drums stand as simple shields against accidents or sabotage. Besides mechanical risks, the secure design fights off inadvertent tampering—a big deal as public trust in medicine teeters after incidents from counterfeiters or low-cost foreign sources. While no packaging can outlaw every mistake, investments in reliable drums and clear tracking show respect for patients' health. Trust builds slowly, one well-packed shipment at a time.
Innovators can push things further. Smarter packaging could help fight waste and streamline audits. I’ve seen companies try embedded sensors in drum lids to track exposure to dampness or heat over time. These digital tags mean no one needs to open a drum to know if the powder inside is still good. As the industry tweaks packaging, future solutions will probably mix security with sustainability, cutting out single-use plastics or offering reusable, tamper-proof bins. Even small advances make a difference in keeping excipients like OP-40 safe and reliable for patients around the world.
Names | |
Preferred IUPAC name | octylphenol polyoxyethylene ether |
Other names |
Polyoxyethylene Octylphenol Ether 40 Octoxynol-40 Triton X-405 Polyethylene Glycol Mono(octylphenyl) Ether POE(40) Octylphenol Ether |
Pronunciation | /ˈɒk.tɪlˌfiː.nɒl ˌpɒl.iˌɒk.siˌiː.θəl.iːn ˈiː.θər ˌfɔːr.tiː/ |
Identifiers | |
CAS Number | 9002-93-1 |
Beilstein Reference | 1866729 |
ChEBI | CHEBI:53743 |
ChEMBL | CHEMBL2107721 |
ChemSpider | 21366679 |
DrugBank | |
ECHA InfoCard | ECHA InfoCard: 100.154.114 |
EC Number | 9036-19-5 |
Gmelin Reference | 3717917 |
KEGG | C06617 |
MeSH | D009808 |
PubChem CID | 67315 |
RTECS number | MD0905000 |
UNII | X8I02IL5G9 |
UN number | UN3082 |
CompTox Dashboard (EPA) | The CompTox Dashboard (EPA) identifier for **Octylphenol Polyoxyethylene Ether 40 (Op-40)** is: ``` DTXSID8022877 ``` |
Properties | |
Chemical formula | (C8H17C6H4O(C2H4O)40H) |
Molar mass | 2094 g/mol |
Appearance | Appearance: White to light yellow paste |
Odor | Odorless |
Density | 1.08 g/cm³ |
Solubility in water | Soluble in water |
log P | 4.5 |
Acidity (pKa) | 4.85 |
Basicity (pKb) | “4.75 (as an approximate pKb value for Octylphenol Polyoxyethylene Ether 40)” |
Refractive index (nD) | 1.4450 |
Viscosity | 80~150 mPa.s (25°C) |
Dipole moment | 4.10 D |
Pharmacology | |
ATC code | A04899 |
Hazards | |
Main hazards | Causes skin and eye irritation. Harmful if swallowed. May cause respiratory irritation. |
GHS labelling | GHS02, GHS07, GHS09 |
Pictograms | ☣️⚠️💧 |
Signal word | Warning |
Hazard statements | No hazard statements. |
Precautionary statements | Precautionary statements: P264, P280, P305+P351+P338, P337+P313, P302+P352, P332+P313 |
NFPA 704 (fire diamond) | 2-1-0 |
Flash point | >100°C |
Lethal dose or concentration | Lethal Dose (LD50): Oral, rat: >2000 mg/kg |
LD50 (median dose) | LD50 (median dose): Rat oral LD50 >2000 mg/kg |
PEL (Permissible) | PEL (Permissible Exposure Limit) for Octylphenol Polyoxyethylene Ether 40 (Op-40) is not specifically established by OSHA or other major regulatory agencies for this compound. |
REL (Recommended) | 280 mg/m³ |
Related compounds | |
Related compounds |
Octylphenol Polyoxyethylene Ether 10 (Op-10) Octylphenol Polyoxyethylene Ether 20 (Op-20) Nonylphenol Polyoxyethylene Ether (NPE) Ethoxylated Octylphenol Tween 40 (Polysorbate 40) Polyethylene Glycol (PEG) Poloxamer Triton X-100 |